

**CONEMAUGH HEALTH SYSTEM
Memorial Medical Center**

RESEARCH POLICY MANUAL

**TITLE: INVESTIGATOR FINANCIAL DISCLOSURE AND CONFLICTS OF
INTEREST IN CLINICAL RESEARCH STUDIES**

STATEMENT OF POLICY:

Conemaugh Health System has a strong commitment to the principle of open and objective inquiry in the conduct of its education, research, and service missions. To promote and protect this objectivity, CHS has long-standing policies concerning conflict of interest. (See Policy C-12-*Conflict and Duality of Interest*, in the CHS Organizational Policy Manual).

Conflicts of interest in research may occur when outside financial interest's compromise, or have the appearance of compromising, the professional judgement of a researcher when designing, conducting, or reporting research.

This policy governing financial conflict of interest applies to all PHS-sponsored Investigators of the Institution. The Institutional Official is responsible for ensuring implementation of this policy and may suspend all relevant activities until the financial conflict of interest is resolved or other action deemed appropriate by the Institutional official is implemented. Violation of any part of these policies may also constitute cause for disciplinary or other administrative action pursuant to Institutional policy.

The scope of this policy applies to all research studies involving CHS, CHS affiliates, and employees as Investigators. It also covers all research studies by non-CHS Investigators that involve the services of CHS employees of any CHS facility.

Anyone who is responsible for or in a position to influence the design, review, conduct, or reporting of research must complete a Financial Conflict of Interest Disclosure Form for internally or externally funded research. This policy applies to, but is not limited to, all Principal Investigators, Sub-Investigators, Institutional Review Board (IRB) members, Scientific Review Committee (SRC) members, members of the Administrative Panel for Research Review, and any other individual on the study team with a potential conflict of interest such as Research Coordinator and statistician.

DEFINITIONS

Clinical Trial means any sponsored research study that involves interaction with human subjects and the concurrent investigative use of drugs, biologics, devices or medical or other clinical procedures.

The Administrative Panel for Research Review is the Institution's committee that advises the Institutional Official on conflict of interest matters.

Family means any member of the Investigator's immediate family, specifically, any dependent children and spouse.

Financial Interest means anything of monetary value received or held by an Investigator or an Investigator's Family, whether or not the value is readily ascertainable, including, but not limited to: salary or other payments for services (e.g., consulting fees, honoraria, or paid authorships for other than scholarly works); any equity interests (e.g., stocks, stock options, or other ownership interests); and intellectual property rights and interests (e.g., patents, trademarks, service marks, and copyrights), upon receipt of royalties or other income related to such intellectual property rights and interests.

Financial Interest does NOT include:

- a) salary, royalties, or other remuneration from the Institution;
- b) income from the authorship of academic or scholarly works;
- c) income from seminars, lectures, or teaching engagements sponsored by or from advisory committees or review panels for U.S. Federal, state or local governmental agencies; U.S. institutions of higher education; research institutes affiliated with institutions of higher education, academic teaching hospitals, and medical centers; or
- d) equity interests or income from investment vehicles, such as mutual funds and retirement accounts, so long as the Investigator does not directly control the investment decisions made in these vehicles.

For Investigators, *Financial Interest* also includes any reimbursed or sponsored travel undertaken by the Investigator and related to his/her institutional responsibilities. This includes travel that is paid on behalf of the Investigator as well as travel that is reimbursed, even if the exact monetary value is not readily available. It excludes travel reimbursed or sponsored by U.S. Federal, state or local governmental agencies, U.S. institutions of higher education, research institutes affiliated with institutions of higher education, academic teaching hospitals, and medical centers.

Significant Financial Interest means a Financial Interest that reasonably appears to be related to the Investigator's Institutional Responsibilities, and:

- a) if with a publicly traded entity, the aggregate value of any salary or other payments for services received during the 12 month period preceding the disclosure, and the value of any equity interest during the 12 month period preceding or as of the date of disclosure, exceeds \$5,000; or
- b) if with a non-publicly traded entity, the aggregate value of any salary or other payments for services received during the 12 month period preceding the disclosure exceeds \$5,000; or
- c) if with a non-publicly-traded company, is an equity interest of any value during the 12 month period preceding or as of the date of disclosure; or

- d) is income exceeding \$5,000 related to intellectual property rights and interests not reimbursed through the Institution, or
- e) is reimbursed or sponsored travel related to their institutional responsibilities.

Financial Conflict of Interest means a Significant Financial Interest that the Institution reasonably determines could directly and significantly affect the design, conduct or reporting of PHS-sponsored research.

Institutional Official means the individual within the Institution that is responsible for the solicitation and review of disclosures of significant financial interests including those of the Investigator's Family related to the Investigator's institutional responsibilities. For the purposes of this policy, the Institutional Official is designated as the Chief Medical Officer.

Institutional responsibilities means the Investigator's professional responsibilities associated with his or her Institutional appointment or position, such as research, teaching, clinical activities, administration, and institutional, internal and external professional committee service.

Investigator means any individual who is responsible for the design, conduct, or reporting of PHS sponsored research, or proposals for such funding. This definition is not limited to those titled or budgeted as principal investigator or co-investigator on a particular proposal, and may include study coordinators, residents, statisticians, graduate students and other research staff. The definition may also include collaborators or consultants as appropriate.

Public Health Service or *PHS* means the Public Health Service of the U.S. Department of Health and Human Services, and any components of the PHS to which the authority of the PHS may be delegated. The components of the PHS include, but are not limited to: Agency for Healthcare Research and Quality (AHRQ), Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention (CDC), Centers for Medicare and Medicaid Services (CMS), Food and Drug Administration (FDA), Health Resources and Services Administration (HRSA), Indian Health Service, National Institutes of Health (NIH), and Substance Abuse and Mental Health Services Administration (SAMHSA).

Research means a systematic investigation, study, or experiment designed to contribute to generalizable knowledge relating broadly to public health, including behavioral and social-sciences research. The term encompasses basic and applied research (e.g., a published article, book or book chapter) and product development (e.g., a diagnostic test or drug).

Sponsored Project means an internally or externally funded clinical trial, teaching or instruction, research or service project.

REQUIREMENTS:

CONFLICT OF INTEREST:

This policy is predicated on the expectation that Investigators should conduct their affairs so as to avoid or minimize conflicts of interest, and must respond appropriately when conflicts of interest arise. To that end, this policy informs Investigators about situations that generate conflicts of interest related to research, provides mechanisms for Investigators and the Institution to manage those conflicts of interest that arise, and describes situations that are prohibited. Every Investigator has an obligation to become familiar with, and abide by, the provisions of this policy. If a situation raising questions of conflict of interest arises, an Investigator should discuss the situation with the Institutional Official.

1) DISCLOSURE OF FINANCIAL INTERESTS

All Investigators are required to disclose their outside financial interests related to research as defined above to the Institution on an annual and on an ad hoc basis, as described below. The Institutional Official or designee is responsible for the distribution, receipt, processing, review and retention of disclosure forms. The Office of Research Administration will assist with the review of these forms and processes.

a) Annual Disclosures

All Investigators must disclose their Significant Financial Interests that are related to the investigator's research or institutional responsibilities to the Institution, through the Institutional Official, on an annual basis. All forms should be submitted to the Institutional Official or designee by January 31.

b) Ad hoc Disclosures

In addition to annual disclosure, certain situations require ad hoc disclosure. All Investigators must disclose their Significant Financial Interests to the Institution, through the Institutional Official.

Prior to entering into PHS-sponsored projects or applications for PHS-sponsored projects, where the Investigator has a Significant Financial Interest, the Investigator must affirm the currency of the annual disclosure or submit to the Institutional Official an ad hoc updated disclosure of his or her Significant Financial Interests with the outside entity. The Institution will not submit a research proposal unless the Investigator(s) have submitted such ad hoc disclosures.

In addition, all Investigators must submit to the Institutional Official an ad hoc disclosure of any Significant Financial Interest they acquire or discover during the course of the year within thirty (30) days of discovering or acquiring the Significant Financial Interest.

c) Travel

Investigators must also disclose reimbursed or sponsored travel related to their institutional responsibilities, as defined above in the definition of Financial Interest and Significant Financial Interest. Such disclosures must include, at a minimum, the purpose of the trip, the identity of the sponsor/organizer, the destination, the duration, and, if known, the monetary value. The Institutional Official will determine if additional information is needed (e.g., the monetary value if not already disclosed) to determine whether the travel constitutes a Financial Conflict of Interest with the Investigator's research.

2) REVIEW AND DECISION OF THE INSTITUTIONAL OFFICIAL

If the disclosure form reveals a Significant Financial Interest, it will be reviewed promptly by the Institutional Official for a determination of whether it constitutes a Financial Conflict of Interest. If a Financial Conflict of Interest exists, the Institutional Official will take action to manage the financial conflict of interest including the reduction or elimination of the conflict, as appropriate.

A Financial Conflict of Interest will exist when the Institutional Official determines that a Significant Financial Interest could directly and significantly affect the design, conduct, or reporting of sponsored research. This determination is based on an analysis that includes, but is not limited to:

1. the nature of the science;
2. the nature of the overlapping interests;
3. how closely the interest is tied to the research;
4. the degree to which the interest may be affected by the research;
5. the degree of risk that the research poses to human subjects and the integrity of the research; and
6. the degree to which the COI can be effectively managed.

If the Institutional Official determines that there is a Financial Conflict of Interest that can be managed, a written management plan will be developed. No PHS sponsored research funds may be expended and no research may begin until the affected Investigator formally agrees to the proposed management strategies and signs the written management plan.

Management plans may include, but are not limited to the following actions:

- Public disclosures of SFIs in abstracts, publications, presentations, press releases, and applications of proposals for research funding;
- Disclosure of financial conflicts of interests to participants

- Monitoring of research by independent reviewers of an oversight committee
- Selection of a non-conflicted PI;
- Change of personnel or personnel responsibilities, or disqualification of personnel from participating in all or a portion of the research;
- Reduction or elimination of the financial interest;
- Severance of relationships that create actual or potential conflicts;
- Refusal by the Institution to enter into a research agreement if a COI cannot be managed effectively;
- Participation of non-conflicted person(s) in evaluation of the research data and/or development of manuscripts;

The Institutional Official will periodically review the ongoing activity; monitor the conduct of the activity (including use of students and residents), to ensure open and timely dissemination of the research results, and to otherwise oversee compliance with the management plan.

3) CLINICAL TRIALS

Review of Significant Financial Interests Related to Clinical Trials

Clinical trials involve particularly sensitive issues if the Investigator has a Financial Interest related to the clinical trial.

- b) Recipients of federal funds from an awardee institution must comply with the Financial Conflict of Interest regulation. Each Investigator planning to apply for or receiving funds or other support for research, including clinical trials, education, or service activities shall disclose any Financial Interest of the Investigator and/or the Investigator's Immediate Family that would reasonably appear to be affected by the research, education, or service activities funded, or proposed for funding.
- c) The following additional provisions shall apply in the case of human subject research:
 - The PI may identify possible subjects for the protocol but may not participate in enrollment
 - The PI may not administer the informed consent

- The informed consent document shall include a disclosure of the existence of the PI's financial interest, in a form approved by the IRB
 - The PI will not be involved in subjective assessments of eligibility criteria and intervention outcomes
 - Modification of the research plan;
 - Appointment of an independent monitor capable of taking measures to protect the design, conduct and reporting of the research against bias resulting from the financial conflict of interest;
 - In the event that the IRB is not in agreement with the proposed COI management plan, and an agreement cannot be reached following the above procedures, the decision to grant approval of the protocol remains with the IRB.
- d) In the event of non-compliance with reporting and/or management of a financial conflict of interest involving a PHS-sponsored clinical research project whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment as required by this Policy, the investigator must disclose the financial conflicts of interest in each public presentation of the results of the affected PHS-sponsored research and request an addendum to previously published presentations.

4) REPORTING TO PHS

The Institutional Official will report financial conflicts of interest or non-compliance to PHS in accordance with PHS regulations. If the funding for the Research is made available from a prime PHS-awardee, such reports shall be made to the prime awardee prior to the expenditure of any funds and within 60 days of any subsequently identified financial conflict of interest such that the prime awardee may fulfill their reporting obligations to the PHS.

5) INVESTIGATOR NON-COMPLIANCE

a) Disciplinary Action

In the event of an Investigator's failure to comply with this Policy, the Institutional Official may suspend all relevant activities or take other disciplinary action until the matter is resolved or other action deemed appropriate by the Institutional Official is implemented.

A Institutional Official's decision to impose sanctions on an Investigator because of

INVESTIGATOR FINANCIAL DISCLOSURE AND CONFLICTS OF INTEREST IN CLINICAL RESEARCH
STUDIES
Page 7 of 10
1/2013

failure to comply with this Policy, or failure to comply with the decision of the Institutional Official, will be described in a written explanation of the decision to the investigator, Administrative Panel for Research Review, and, where applicable, the IRB, and will notify the individual of the right to appeal the decision. The institution will promptly notify the PHS Awarding Component of the action taken or to be taken. If the funding for the research is made available from a prime PHS awardee, such notification shall be made promptly to the prime awardee for reporting to PHS.

b) Retrospective Review

In addition, if the Institutional Official determines that a Financial Conflict of Interest was not identified or managed in a timely manner, including but not limited to an Investigator's failure to disclose a Significant Financial Interest that is determined to be a Financial Conflict of Interest, or failure by an Investigator to materially comply with a management plan for a Financial Conflict of Interest, an audit committee appointed by the Institutional Official will complete a retrospective review of the Investigator's activities and the PHS-sponsored research project to determine whether the research conducted during the period of non-compliance was biased in the design, conduct or reporting of the research.

Documentation of the retrospective review shall include the project number, project title, PI, name of Investigator with the Financial Conflict of Interest, name of the entity with which the Investigator has the Financial Conflict of Interest, reason(s) for the retrospective review, detailed methodology used for the retrospective review, and findings and conclusions of the review.

The Institutional Official will update any previously submitted report to the PHS or the prime PHS-awardee relating to the research, specifying the actions that will be taken to manage the Financial Conflict of Interest going forward. This retrospective review will be completed in the manner and within the time frame established in PHS regulations. If bias is found, the institution will promptly notify the PHS Awarding Component and submit a mitigation report in accordance with the PHS regulations. The mitigation report will identify elements documented in the retrospective review, a description of the impact of the bias on the research project and the plan of action to eliminate or mitigate the effect of the bias.

6) TRAINING

Each Investigator must complete training on this Policy, the investigator's responsibilities regarding disclosure and the PHS regulations prior to engaging in research funded by PHS, and at least every four years thereafter. They must also complete training within a reasonable period of time as determined by the Institutional Official in the event that this Policy is substantively amended in a manner that affects the requirements of Investigators,

if the investigator is new to the institution, or if it is determined that the Investigator has not complied with this policy or with a management plan related to their activities.

7) RECORD RETENTION

The Institutional Official or designee will retain all disclosure forms, conflict management plans, and related documents for a period of three years from the date the final expenditure report is submitted to the PHS or to the prime PHS awardee, unless any litigation, claim, financial management review, or audit is started before the expiration of the three year period, the records shall be retained until all litigation, claims or audit findings involving the records have been resolved and final action taken.

8) CONFIDENTIALITY

To the extent permitted by law, all disclosure forms, conflict management plans, and related information will be confidential. However, the Institution may be required to make such information available to the PHS Awarding Component and/or HHS, to a requestor of information concerning financial conflict of interest related to PHS funding or to the primary entity who made the funding available to the Institution, if requested or required. If the Institution is requested to provide disclosure forms, conflict management plans, and related information to an outside entity, the Investigator will be informed of this disclosure.

9) PUBLIC ACCESSIBILITY

Prior to the expenditure of funds, the Institution will respond to any requestor within five business days of the request, information concerning any Significant Financial Interest that meets the following criteria:

- a) The Significant Financial Interest was disclosed and is still held by the senior and key personnel;
- b) A determination has been made that the Significant Financial Interest is related to the PHS-funded research; and
- c) A determination has been made that the Significant Financial Interest is a Financial Conflict of Interest.

The information to be made available shall be consistent with the requirements of the PHS regulation.

10) REGULATORY AUTHORITY

This policy implements the requirements of 42 CFR 50 Subpart F and 45 CFR 94; where there are substantive differences between this policy and the requirements, the requirements shall take precedence.

RESPONSIBILITY:

The CHS Office of Research Administration is responsible for implementation of this policy.

RELATED POLICIES/PROCEDURES/GUIDELINES AND FORMS:

The Final Rule, “Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective Contractors.”[42 CFR, Part 50, Subpart F and 45 CFR, Part 90]

SIGNATURE:

David Carlson, DO
CMO

ORIGINAL POLICY DATED: 1/2013

REVIEWED / REVISED:

NEXT REVIEW DATE: 1/2013